Page last updated: 2024-08-24

plerixafor and Granulocytic Leukemia, Chronic

plerixafor has been researched along with Granulocytic Leukemia, Chronic in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Calandra, G; Dillmann, F; Fruehauf, S; Laufs, S; Sperandio, M; Veldwijk, MR; Wenz, F; Zeller, J1
Fava, C; Saglio, G1
Azab, AK; Bronson, R; Christie, AL; Ghobrial, IM; Griffin, JD; Kung, AL; Manley, PW; Weisberg, E1
Agarwal, A; Deininger, MW; Druker, BJ; Fleischman, AG; Loriaux, M; Luty, S; MacKenzie, R; Petersen, CL; Woltjer, RL1

Other Studies

4 other study(ies) available for plerixafor and Granulocytic Leukemia, Chronic

ArticleYear
Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:10

    Topics: Animals; Benzamides; Benzylamines; Cell Adhesion; Cell Line; Cell Line, Tumor; Chemokine CXCL12; Coculture Techniques; Cyclams; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Heterocyclic Compounds; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplasm Proteins; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, CXCR4; Stromal Cells

2009
Inhibition of stromal cell-derived factor-1/CXCR4 axis for the cure of BCR-ABL positive chronic myeloid leukemia.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:10

    Topics: Antiviral Agents; Benzamides; Benzylamines; Bone Marrow; Cell Adhesion; Cell Line, Tumor; Chemokine CXCL12; Cyclams; Drug Resistance, Neoplasm; Heterocyclic Compounds; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, CXCR4; Secondary Prevention; Stromal Cells

2009
Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib.
    Leukemia, 2012, Volume: 26, Issue:5

    Topics: Animals; Antineoplastic Agents; Benzylamines; Bone Marrow Cells; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Cyclams; Drug Resistance, Neoplasm; Flow Cytometry; Heterocyclic Compounds; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Pyrimidines; Receptors, CXCR4; Stromal Cells

2012
Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML.
    Blood, 2012, Sep-27, Volume: 120, Issue:13

    Topics: Animals; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzylamines; Blotting, Western; Cell Line, Tumor; Chemokine CXCL12; Cyclams; Dasatinib; Female; Flow Cytometry; Fusion Proteins, bcr-abl; Heterocyclic Compounds; Imatinib Mesylate; Immunoenzyme Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Nervous System Diseases; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, CXCR4; Thiazoles

2012